CD34 and acute myeloid leukemia: The ChoKɑ1 inhibitors were active in reducing the proliferation of primary human AML and CB CD34+ cells at different IC50 ranging from nanomolar concentrations with ICL‐CCIC‐0019 and the non‐commercial compound EB‐3P41, 42 to lower and higher micromolar concentrations with RSM‐932A and the non‐commercial compound EB‐3D41, 42, 43, 44 (Figure 6C).